Brief: Tarsus Pharmaceuticals Q4 Basic EPS USD -1.31
27/02/2024 11:00
Feb 27 (Reuters) - Tarsus Pharmaceuticals Q4 operating expenses USD 57.526 million. * Q4 net income USD -41.902 million
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)